Phase II multicenter study of epirubicin for hormone-resistant prostatic cancer with measurable soft tissue disease.
Twenty-six patients with prostatic cancer were treated with courses of epirubicin at 3-week intervals, starting at an initial intravenous dose of 75 mg/m2. All patients had progressive disease after orchiectomy and/or antiandrogen therapy and had measurable soft tissue lesions. There were three partial responders (response rate: 12%; 95% confidence limits: 4-29%). Major toxicity was myelosuppression, and there were two drug-related deaths. Epirubicin in this dose and schedule cannot be recommended for treatment of prostatic cancer.
Tannock
I F
IF
Princess Margaret Hospital, Toronto, Ontario, Canada.
Erwin
T J
TJ
Stewart
D J
DJ
Fontaine
B
B
Gupta
S
S
D000368:Aged; D015251:Epirubicin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy / Q000556:secondary*; D016019:Survival Analysis
D015251:Epirubicin